Interplay of Genetic Risk Factors (CHRNA5-CHRNA3-CHRNB4) and Cessation Treatments in Smoking Cessation Success
- 1 July 2012
- journal article
- research article
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 169 (7), 735-742
- https://doi.org/10.1176/appi.ajp.2012.11101545
Abstract
Objective: Smoking is highly intractable, and the genetic influences on cessation are unclear. Identifying the genetic factors affecting smoking cessation could elucidate the nature of tobacco dependence, enhance risk assessment, and support development of treatment algorithms. This study tested whether variants in the nicotinic receptor gene cluster CHRNA5-CHRNA3-CHRNB4 predict age at smoking cessation and relapse after an attempt to quit smoking. Method: In a community-based, cross-sectional study (N=5,216) and a randomized comparative effectiveness smoking cessation trial (N=1,073), the authors used Cox proportional hazard models and logistic regression to model the relationships of smoking cessation (self-reported quit age in the community study and point-prevalence abstinence at the end of treatment in the clinical trial) to three common haplotypes in the CHRNA5-CHRNA3-CHRNB4 region defined by rs16969968 and rs680244. Results: The genetic variants in the CHRNA5-CHRNA3-CHRNB4 region that predict nicotine dependence also predicted a later age at smoking cessation in the community sample. In the smoking cessation trial, haplotype predicted abstinence at end of treatment in individuals receiving placebo but not among individuals receiving active medication. Haplotype interacted with treatment in affecting cessation success. Conclusions: Smokers with the high-risk haplotype were three times as likely to respond to pharmacologic cessation treatments as were smokers with the low-risk haplotype. The high-risk haplotype increased the risk of cessation failure, and this increased risk was ameliorated by cessation pharmacotherapy. By identifying a high-risk genetic group with heightened response to smoking cessation pharmacotherapy, this work may support the development of personalized cessation treatments.Keywords
This publication has 38 references indexed in Scilit:
- Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5‐A3‐B4) predict severity of nicotine addiction and response to smoking cessation therapyAmerican Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2011
- Acetylcholine Receptor (AChR) α5 Subunit Variant Associated with Risk for Nicotine Dependence and Lung Cancer Reduces (α4β2)2α5 AChR FunctionMolecular Pharmacology, 2010
- Multiple Independent Loci at Chromosome 15q25.1 Affect Smoking Quantity: a Meta-Analysis and Comparison with Lung Cancer and COPDPLoS Genetics, 2010
- Genome-wide meta-analyses identify multiple loci associated with smoking behaviorNature Genetics, 2010
- Prospective Association of Dopamine-Related Polymorphisms with Smoking Cessation in General CarePharmacogenomics, 2010
- A Randomized Placebo-Controlled Clinical Trial of 5 Smoking Cessation PharmacotherapiesArchives of General Psychiatry, 2009
- Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependenceNicotine & Tobacco Research, 2007
- Catechol-O-Methyltransferase (COMT) Gene Variants Predict Response to Bupropion Therapy for Tobacco DependenceBiological Psychiatry, 2007
- Biochemical verification of tobacco use and cessationNicotine & Tobacco Research, 2002
- Cigarette Smoking and Progression of AtherosclerosisPublished by American Medical Association (AMA) ,1998